Radius Health, 3M Expand Alliance

Radius Health, Inc. and 3M Drug Delivery Systems have entered an exclusive partnership for the development and commercialization of BA058-transdermal (TD), a synthetic peptide analog of human parathyroid hormone related protein (hPTHrP), a bone building anabolic compound, for the potential treatment of osteoporosis. This agreement expands the development agreement entered in May 2011 for BA058-TD.
 
BA058-TD is being studied in a Phase II trial in healthy postmenopausal women with osteoporosis. BA058-TD is a short-wear time patch using 3M’s Microstructured Transdermal System technology. 
 
“We are excited that 3M Drug Delivery Systems, which has long demonstrated a commitment to quality, safety and innovation, is partnering with us to bring a novel approach of drug delivery to the underserved osteoporosis patient population,” said Michael Wyzga, Radius president and chief executive officer. “Our study data for BA058-TD showed that a five-minute wear time of the patch delivers peak drug levels consistent with subcutaneous injection and we hope to see increased patient compliance with 3M’s innovative technology.”
 
“We are pleased to be part of Radius’ mission of advancing therapeutics for healthy aging with its deep expertise in osteoporosis,” said Ingrid Blair, MTS/TDD business vice president of 3M Drug Delivery Systems. “With this exclusive agreement, 3M and Radius demonstrate our commitment to this innovative therapeutic treatment and this unique drug delivery mechanism. We believe this new drug potentially will improve the health of patients with severe osteoporosis and that 3M’s microneedle patch technology may improve medication compliance among patients.”